Angelini secures global rights to brain health asset

21 October 2024

Angelini Pharma, part of Italy’s Angelini Industries, has entered into an exclusive option agreement with South Korea-based Cureverse for the global development and commercialization of a clinical-stage brain health asset.

The deal focuses on CV-01, a novel compound with potential applications across several neurological conditions, including epilepsy. CV-01 is currently in Phase I clinical trials in South Korea for Alzheimer’s disease.

Angelini will lead global development, with the option to license exclusive rights for CV-01 in all regions except South Korea, China, Hong Kong, Macau, and Taiwan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK